

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

Date: August 13, 2025

To,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai — 400001

BSE Scrip Code- 530057

Subject: Outcome of the Board Meeting

Dear Sir/Madam,

In continuation of our letter Dated August 08, 2025, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday , August 13, 2025 at Registered Office of the Company has inter alia considered and approved the Un-audited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the Quarter ended on 30th June, 2025. **(Enclosed herewith)**

The meeting of Board of Directors of the Company commenced at 3:30 P.M. and concluded at 4:00 P.M.

You are requested to kindly take the same on record and acknowledge.

Thanking You.

For, Vivanza Biosciences Limited

Siddhi Shah
Company Secretary & Compliance Officer
Membership No.: A44885

Encl: As above

Limited review report on the Un-audited Standalone Financial Results for the quarter ended 30th June 2025, pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors,
Vivanza Biosciences Limited
Ahmedabad

We have reviewed the accompanying statement of Un-audited Standalone Financial Results of Vivanza Biosciences Limited ("the Company") for the quarter ended 30th June, 2025, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended.

This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India read with the Circular. Our responsibility is to issue a report on the financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of interim Financial information performed by the Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards as notified under the Companies (India Accounting Standards) Rules, 2015 as specified in Section 133 of the Companies Act 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W



CA Shivam Soni
Proprietor
Membership No. : 178351
UDIN : 25178351BMIRJJ5349

Date : 13/08/2025
Place : Ahmedabad

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

Email Id: info@vivanzabiosciences.com, Website : www.vivanzabiosciences.com, Ph.no.: 079-26870952/53

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025.

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Year Ended	
	30-06-2025	31-03-2025	30-06-2024	31-03-2025	
	Unaudited	Audited	Unaudited	Audited	
1	Income from Operations				
	(a) Revenue from operations	782.06	16.96	42.78	294.28
	(b) Other Income	1.74	1.92	0.32	3.46
	Total Income	783.81	18.89	43.10	297.74
2	Expenses				
	(a) Cost of Materials consumed	-	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	770.95	17.18	32.13	266.77
	(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	(15.63)	69.69	-40.41	-4.29
	(d) Employee benefits expense	9.22	11.25	9.36	36.73
	(e) Finance Cost	7.66	7.92	9.29	35.08
	(f) Depreciation and amortisation expense	0.35	0.28	0.30	1.40
	(g) Other expenses	9.40	8.97	9.78	31.42
	Total Expenses	781.95	115.29	20.45	367.10
3	Profit/(loss) before exceptional items and tax (1-2)	1.86	-96.40	22.65	-69.36
4	Exceptional Items	0.00	0.00	0.00	0.00
5	Profit/(Loss) before tax (3-4)	1.86	-96.40	22.65	-69.36
6	Tax Expense				
	(a) Current tax	0.00	0.00	0.00	0.00
	(b) Deferred tax	0.00	0.14	0.00	0.14
	Total Tax Expenses	0.00	0.14	0.00	0.14
7	Profit / (Loss) for the period from continuing oprations (5-6)	1.86	-96.54	22.65	-69.51
8	Profit (Loss) from discontinuing oprations	0.00	0.00	0.00	0.00
9	Tax Expense of discontinuing oprations	0.00	0.00	0.00	0.00
10	Profit (Loss) from discontinuing oprations (after tax)(8-9)	0.00	0.00	0.00	0.00
11	Other Comprehensive Income				
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	Other Comprehensive Income for the period	0.00	0.00	0.00	0.00
12	Total Comprehensive Income for the period	1.86	-96.54	22.65	-69.51
13	Paid-up equity share capital (Face value of Rs. 1/- each)	400	400	400	400
14	Other Equity	-	-	-	71.53
15	Earnings Per Share (before extraordinary items) (not annualised):				
	(a) Basic	0.0046	-0.24	0.06	-0.17
	(b) Diluted	0.0046	-0.24	0.06	-0.17
16	Earnings Per Share (after extraordinary items) (not annualised):				
	(a) Basic	0.0046	-0.24	0.06	-0.17
	(b) Diluted	0.0046	-0.24	0.06	-0.17

Notes:


1. The above Standalone Un-audited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on August 13, 2025. The Audit under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Audit Report does not contain any observation which could have an impact on the results for the quarter/year ended June 30, 2025.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company is in the business of Pharmaceuticals and Agro Trading & Consultancy related Activities.

Date : 13/08/2025
Place : Ahmedabad

For, VIVANZA BIOSCIENCES LIMITED



Jayendra Mehta
Jayendra Mehta
Managing Director

DIN: 08210602

Limited review report on the Un-audited Consolidated Financial Results for the quarter ended 30th June 2025, pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors,
M/s Vivanza Biosciences Limited

We have reviewed the accompanying statement of Unaudited Consolidated Financial results of M/s Vivanza Biosciences Limited ("the Company") and its subsidiary (the Parent and its Subsidiary together referred to as "the Group"), for the quarter ended 30th June,2025, ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 , as amended.

This statement is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other accounting principles generally accepted in India read with the Circular. Our responsibility is to issue a report on the consolidated financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial information performed by the Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statements includes the results of following entity ("the Subsidiary"): Vivanza Lifesciencies Private Limited.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards as notified under the Companies (India Accounting Standards) Rules,2015 as specified in Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



We did not review the financial results of subsidiary included in the consolidated unaudited financial results. These interim financial statement of the subsidiary have been reviewed by other auditor whose report has been furnished to us by the management and our conclusion on the statement, so far as it relates to amounts and disclosures included in respect of this subsidiary is based solely on the report of the auditor of the company and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the matter.



For SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W

Shivam

CA Shivam Soni
Proprietor
Membership No. : 178351
UDIN : 25178351BMIRJK5443

Date : 13/08/2025
Place : Ahmedabad

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054
CIN : L24110GJ1982PLC005057

Email Id: info@vivanzabiosciences.com, Website : www.vivanzabiosciences.com, Ph.no : 079-26870952/53

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025.


(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Year Ended
	30-06-2025	31-03-2025	30-06-2024	31-03-2025
	Unaudited	Audited	Unaudited	Audited
1 Income from Operations				
(a) Revenue from operations				
(b) Other Income	893.92	48.30	243.92	742.33
Total Income	1.74	4.62	0.32	6.15
2 Expenses	895.66	52.91	244.24	748.48
(a) Cost of Materials consumed				
(b) Purchase of stock-in-trade	-	0.00	0.00	0.00
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	961.25	47.79	230.26	707.74
(d) Employee benefits expense	(105.50)	69.56	(47.91)	(25.68)
(e) Finance Cost	13.64	15.23	15.26	57.51
(f) Depreciation and amortisation expense	7.66	7.98	9.29	35.14
(g) Other expenses	0.35	0.28	0.30	1.40
Total Expenses	9.57	11.04	10.46	38.94
3 Profit/(loss) before exceptional items and tax (1-2)	886.96	151.88	217.66	815.05
4 Exceptional Items	8.70	-98.97	26.58	-66.57
5 Profit/(Loss) before tax (3-4)	0.00	0.00	0.00	0.00
6 Tax Expense	8.70	-98.97	26.58	-66.57
(a) Current tax				
(b) Deferred tax	0.00	0.70	0.00	0.70
Total Tax Expenses	0.00	0.14	0.00	0.14
7 Profit / (Loss) for the period from continuing oprations (5-6)	0.00	0.84	0.00	0.84
8 Profit (Loss) from discontinuing oprations	8.70	-99.81	26.58	-67.41
9 Tax Expense of discontinuing oprations	0.00	0.00	0.00	0.00
10 Profit (Loss) from discontinuing oprations (after tax)(8-9)	0.00	0.00	0.00	0.00
11 Share of Profit / (Loss) of associates *	0.00	0.00	0.00	0.00
12 Minority Interest *	0.00	0.00	0.00	0.00
13 Other Comprehensive Income	0.00	0.00	0.00	0.00
A(i) Items that will not be reclassified to profit or loss				
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
Other Comprehensive Income for the period	0.00	0.00	0.00	0.00
14 Total Comprehensive Income for the period	0.00	0.00	0.00	0.00
15 Total Comprehensive Income attributable to :	8.70	-99.81	26.58	-67.41
Share of Profit / (Loss) of associates *				
Minority Interest *	0.00	0.00	0.00	0.00
16 Paid-up equity share capital (Face value of Rs.1/- each)	0.00	0.00	0.00	0.00
17 Other Equity	400	400	400	400
18 Earnings Per Share (before extraordinary items) (not annualised):				
(a) Basic				-3.59
(b) Diluted	0.02	-0.25	0.07	-0.17
19 Earnings Per Share (after extraordinary items) (not annualised):	0.02	-0.25	0.07	-0.17
(a) Basic				
(b) Diluted	0.02	-0.25	0.07	-0.17

Notes:

1. The above Consolidated Un-audited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on August 13, 2025. The Audit under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Audit Report does not contain any observation which could have an impact on the results for the quarter/year ended June 30, 2025.
2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.
3. The Company is in the business of Pharmaceuticales and Agro Trading & Consultancy related Activities.

For, VIVANZA BIOSCIENCES LIMITED



Jayendra Mehta
Managing Director
DIN : 08210602

Date : 13/08/2025
Place : Ahmedabad